NSAIDs, prostaglandins and the neonatal kidney

References

• Smith W. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992; 263: F181–F191
   PubMed Web of Science ®Google Scholar
• Antonucci R, Cuzzolin L, Arceri A, Fanos V. Urinary prostaglandin E2 in the newborn and infant. Prostaglandins Other Lipid Mediat 2007; 84: 1–13
   PubMed Web of Science ®Google Scholar
• Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties and functions. Physiol Rev 1999; 79: 1193–1226
   PubMed Web of Science ®Google Scholar
• Breyer M D, Breyer R M. Prostaglandin receptors: their role in regulating renal function. Curr Opin Nephrol Hypertens 2000; 9: 23–29
   PubMed Web of Science ®Google Scholar
• Langhendries J P, Van Overmeire B. Prostaglandines, anti-inflammatoires non stéroïdiens (AINS) et rein périnatal: un subtil compromise. Médicaments, néphrotoxicité, insuffisance rénale aiguë chez le nouveau-né, J P Guignard, J B Gouyon, U Simeoni. Elsevier, Amsterdam 2001; 36–59
   Google Scholar
• Agostiniani R, Mariotti P, Cataldi L, Fanos V, Sani S, Zaccaron A, Cuzzolin L. Role of renal PGE2 in the adaptation from foetal to extrauterine life in term and preterm infants. Prostaglandins Leukot Essent Fatty Acids 2002; 67: 373–377
   PubMed Web of Science ®Google Scholar
• Seri I, Hajdu J, Kiszel J, Tulassay T, Aperia A. Effect of low-dose dopamine infusion on urinary prostaglandin E2 excretion in sick, preterm infants. Eur J Pediatr 1988; 147: 616–620
   PubMed Web of Science ®Google Scholar
• Hoch B, Bernhard M, Seyberth H W, Watzer B, Schweer H. Neonatal urinary prostanoid excretion. Prostaglandins Other Lipid Mediat 2000; 60: 9–14
   PubMed Web of Science ®Google Scholar
• Cuzzolin L, Dal Cerè M, Fanos V. NSAID-induced nephrotoxicity from the fetus to the child. Drug Saf 2001; 24: 9–18
   PubMed Web of Science ®Google Scholar
• Antonucci R, Cuzzolin L, Arceri A, Dessì A, Fanos V. Changes in urinary PGE2 after ibuprofen treatment in preterm infants with patent ductus arteriosus. Eur J Clin Pharmacol 2009; 65: 223–230
   PubMed Web of Science ®Google Scholar
• Knights K M, Tsoutsikos P, Miners J O. Novel mechanisms of nonsteroidal anti-inflammatory drug-induced renal toxicity. Expert Opin Drug Metab Toxicol 2005; 1: 399–408
   PubMedGoogle Scholar
• Shaffer C L, Gal P, Ransom J L, Carlos R Q, Smith M S, Davey A M, Dimaguila M A, Brown Y L, Schall S A. Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus. Crit Care Med 2002; 30: 343–348
   PubMed Web of Science ®Google Scholar
• Akima S, Kent A, Reynolds G J, Gallagher M, Falk M C. Indomethacin and renal impairment in neonates. Pediatr Nephrol 2004; 19: 490–493
   PubMed Web of Science ®Google Scholar
• Van Overmeire B, Follens I, Hartmann S, Creten W L, Van Acker K J. Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child Foetal Neonatal Ed 1997; 76: F179–F184
   PubMed Web of Science ®Google Scholar
• Van Overmeire B, Smets K, Lecoutere D, Van de Broek H, Weyler J, Degroote K, Langhendries J P. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000; 343: 674–681
   PubMed Web of Science ®Google Scholar
• Lago P, Bettiol T, Salvadori S, Pitassi I, Vianello A, Chiandetti L, Saia O S. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomized controlled trial. Eur J Pediatr 2002; 161: 202–207
   PubMed Web of Science ®Google Scholar
• Pezzati M, Vangi V, Biagiotti R, Bestini G, Cianciulli D, Rubaltelli F F. Effect of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr 1999; 135: 733–738
   PubMed Web of Science ®Google Scholar
• Thomas R L, Parker G C, Van Overmeire B, Aranda J V. A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. Eur J Pediatr 2005; 164: 135–140
   PubMed Web of Science ®Google Scholar
• Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2008; 1: CD003481
   Google Scholar
• Guignard J P. The adverse renal effects of prostaglandin-synthesis inhibitors in the newborn rabbit. Semin Perinatol 2002; 26: 398–405
   PubMed Web of Science ®Google Scholar
• Cuzzolin L, Fanos V, Pinna B, di Marzio M, Perin M, Tramontozzi P, Tonetto P, Cataldi L. Postnatal renal function in preterm newborns: a role of diseases, drugs and therapeutic interventions. Pediatr Nephrol 2006; 21: 931–938
   PubMed Web of Science ®Google Scholar
• Allegaert K, Rayyan M, Anderson B J. Impact of ibuprofen administration on renal drug clearance in the first weeks of life. Methods Find Exp Clin Pharmacol 2006; 28: 519–522
   PubMedGoogle Scholar
• Ojala R, Ala-Houhala M, Ahonen S, Harmoinen A, Turjanmaa V, Ikonen S, Tammela O. Renal follow up of premature infants with and without perinatal indomethacin exposure. Arch Dis Child Fetal Neonatal Ed 2001; 84: F28–F33
   Web of Science ®Google Scholar
• Rodríguez M M, Gómez A H, Abitbol C L, Chandar J J, Duara S, Zilleruelo G E. Histomorphometric analysis of postnatal glomerulogenesis in extremely preterm infants. Pediatr Dev Pathol 2004; 7: 17–25
   PubMed Web of Science ®Google Scholar
• Giniger R P, Buffat C, Millet V, Simeoni U. Renal effects of ibuprofen for the treatment of patent ductus arteriosus in premature infants. J Matern Fetal Neonatal Med 2007; 20: 275–283
   PubMed Web of Science ®Google Scholar